Effect of a $ Pluronic^{®} $ P123 Formulation on the Nitric Oxide-Generating Drug JS-K
Purpose $ O^{2} $-(2,4-dinitrophenyl)1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate] or JS-K is a nitric oxide-producing prodrug of the arylated diazeniumdiolate class with promising anti-tumor activity. JS-K has challenging solubility and stability properties. We aimed to characterize and compare $ Pluronic^{®} $ P123-formulated JS-K (P123/JS-K) with free JS-K. Methods We determined micelle size, shape, and critical micelle concentration of $ Pluronic^{®} $ P123. Efficacy was evaluated in vitro using HL-60 and U937 cells and in vivo in a xenograft in NOD/SCID IL2R$ γ^{null} $ mice using HL-60 cells. We compared JS-K and P123/JS-K stability in different media. We also compared plasma protein binding of JS-K and P123/JS-K. We determined the binding and Stern Volmer constants, and thermodynamic parameters. Results Spherical P123/JS-K micelles were smaller than blank P123. P123/JS-K formulation was more stable in buffered saline, whole blood, plasma and RPMI media as compared to free JS-K. P123 affected the protein binding properties of JS-K. In vitro it was as efficacious as JS-K alone when tested in HL-60 and U937 cells and in vivo greater tumor regression was observed for P123/JS-K treated NOD/SCID IL2R$ γ^{null} $ mice when compared to free JS-K-treated NOD/SCID IL2R$ γ^{null} $ mice. Conclusions $ Pluronic^{®} $ P123 solubilizes, stabilizes and affects the protein binding characteristics of JS-K. P123/JS-K showed more in vivo anti-tumor activity than free JS-K..
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2014 |
---|---|
Erschienen: |
2014 |
Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
---|---|
Enthalten in: |
Pharmaceutical research - 32(2014), 4 vom: 18. Okt., Seite 1395-1406 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Kaur, Imit [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
Anmerkungen: |
© Springer Science+Business Media New York 2014 |
---|
doi: |
10.1007/s11095-014-1542-9 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
OLC206734594X |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | OLC206734594X | ||
003 | DE-627 | ||
005 | 20230518144349.0 | ||
007 | tu | ||
008 | 200819s2014 xx ||||| 00| ||eng c | ||
024 | 7 | |a 10.1007/s11095-014-1542-9 |2 doi | |
035 | |a (DE-627)OLC206734594X | ||
035 | |a (DE-He213)s11095-014-1542-9-p | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q VZ |
084 | |a 15,3 |2 ssgn | ||
084 | |a PHARM |q DE-84 |2 fid | ||
100 | 1 | |a Kaur, Imit |e verfasserin |4 aut | |
245 | 1 | 0 | |a Effect of a $ Pluronic^{®} $ P123 Formulation on the Nitric Oxide-Generating Drug JS-K |
264 | 1 | |c 2014 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
500 | |a © Springer Science+Business Media New York 2014 | ||
520 | |a Purpose $ O^{2} $-(2,4-dinitrophenyl)1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate] or JS-K is a nitric oxide-producing prodrug of the arylated diazeniumdiolate class with promising anti-tumor activity. JS-K has challenging solubility and stability properties. We aimed to characterize and compare $ Pluronic^{®} $ P123-formulated JS-K (P123/JS-K) with free JS-K. Methods We determined micelle size, shape, and critical micelle concentration of $ Pluronic^{®} $ P123. Efficacy was evaluated in vitro using HL-60 and U937 cells and in vivo in a xenograft in NOD/SCID IL2R$ γ^{null} $ mice using HL-60 cells. We compared JS-K and P123/JS-K stability in different media. We also compared plasma protein binding of JS-K and P123/JS-K. We determined the binding and Stern Volmer constants, and thermodynamic parameters. Results Spherical P123/JS-K micelles were smaller than blank P123. P123/JS-K formulation was more stable in buffered saline, whole blood, plasma and RPMI media as compared to free JS-K. P123 affected the protein binding properties of JS-K. In vitro it was as efficacious as JS-K alone when tested in HL-60 and U937 cells and in vivo greater tumor regression was observed for P123/JS-K treated NOD/SCID IL2R$ γ^{null} $ mice when compared to free JS-K-treated NOD/SCID IL2R$ γ^{null} $ mice. Conclusions $ Pluronic^{®} $ P123 solubilizes, stabilizes and affects the protein binding characteristics of JS-K. P123/JS-K showed more in vivo anti-tumor activity than free JS-K. | ||
700 | 1 | |a Kosak, Ken M. |4 aut | |
700 | 1 | |a Terrazas, Moises |4 aut | |
700 | 1 | |a Herron, James N. |4 aut | |
700 | 1 | |a Kern, Steven E. |4 aut | |
700 | 1 | |a Boucher, Kenneth M. |4 aut | |
700 | 1 | |a Shami, Paul J. |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Pharmaceutical research |d Springer US, 1983 |g 32(2014), 4 vom: 18. Okt., Seite 1395-1406 |w (DE-627)130652571 |w (DE-600)843063-9 |w (DE-576)016203372 |x 0724-8741 |7 nnns |
773 | 1 | 8 | |g volume:32 |g year:2014 |g number:4 |g day:18 |g month:10 |g pages:1395-1406 |
856 | 4 | 1 | |u https://doi.org/10.1007/s11095-014-1542-9 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
912 | |a FID-PHARM | ||
912 | |a SSG-OLC-PHA | ||
912 | |a SSG-OLC-DE-84 | ||
912 | |a SSG-OPC-PHA | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_2005 | ||
912 | |a GBV_ILN_2012 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
951 | |a AR | ||
952 | |d 32 |j 2014 |e 4 |b 18 |c 10 |h 1395-1406 |